July 16, 2019
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under the current NDA Company accelerates timeline and now expects resubmission of FUROSCIX NDA with the FDA by mid-year 2020 BURLINGTON, Mass., July...


Research project to investigate potential link between headache pills and early-stage spontaneous abortion
6. January 2020
Cancer patients donate living brain cells to scientists
17. December 2019
The Lundbeck Foundation grants 60 million Danish kroner to bold scientific ideas
11. December 2019


Lundbeckfonden Ventures

Lundbeckfonden Emerge